US 11,717,494 B2
Oral solid cannabinoid oil composition for treating gastrointestinal disorders
Syed M. Shah, Boca Raton, FL (US); and Fred Hassan, Boca Raton, FL (US)
Assigned to Societe des Produits Nestle S.A., Vevey (CH)
Filed by SOCIÉTÉ DES PRODUITS NESTLÉ S.A., Vevey (CH)
Filed on Jan. 8, 2021, as Appl. No. 17/144,784.
Claims priority of provisional application 62/958,392, filed on Jan. 8, 2020.
Prior Publication US 2021/0205235 A1, Jul. 8, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/05 (2006.01); A61K 9/16 (2006.01); A61K 9/50 (2006.01)
CPC A61K 31/05 (2013.01) [A61K 9/1652 (2013.01); A61K 9/1694 (2013.01); A61K 9/5073 (2013.01)] 16 Claims
OG exemplary drawing
 
1. A composition comprising:
an oral multiparticulate dosage form including a plurality of individual particulates, wherein the individual particulates are spheroidal and comprise:
(a) a solid core including an effective amount of cannabinoid oil bound in microcrystalline cellulose (MCC) in a ratio of the cannabinoid oil to the MCC of 0.5:1 to 1.5:1; and
(b) an enteric coating over the solid core,
wherein the individual particulates are selected from the group consisting of:
(i) the individual particulates have an average diameter of 0.5 mm to 1.7 mm and further comprise an enteric coating material and a disintegrant combination configured for the individual particulates to release at least about 50% of the cannabinoid oil in a subject's duodenum for treating inflammation of the duodenum;
(ii) the individual particulates have an average diameter of 0.5 to 1.7 mm and are configured to release at least about 50% of the cannabinoid oil in a subject's jejunum for treating inflammation of the jejunum; and
(iii) the individual particulates have an average diameter of 0.5 to 1.7 mm and are configured to release at least about 50% of the cannabinoid oil in a subject's ileum for treating inflammation of the ileum,
wherein the individual particulates comprise 10% w/w to 50% w/w of the cannabinoid oil, 40% w/w to 75% w/w of the microcrystalline cellulose, 2% w/w to 10% w/w methyl cellulose, and 2% w/w to 35% w/w of the enteric coating.